Creative Enzymes, a global enzyme technology service provider, has launched an AI-integrated biocatalysis platform designed to accelerate enzyme development and bridge the gap between computational predictions and real-world industrial applications. The platform combines computational enzyme engineering with hands-on process development know-how, delivering AI-driven biocatalysis solutions that are predictable in silico and stable at industrial scale.
Traditional enzyme development approaches often fail to meet the speed requirements of iterative product development, particularly in biomanufacturing where the pace of catalyst development is a key constraint. AI brings critical value by predicting enzyme candidates best suited for a given biocatalytic reaction, designing enzymes constrained by process parameters, and leveraging key molecular features to anticipate process performance in advance. This not only speeds up development but also reduces R&D costs by minimizing the need to test myriad variants and lowers the risk of process failure by identifying suitable biocatalysts earlier.
The platform is delivered through three specialized service modules: AI-Driven Biocatalysis Solutions for end-to-end discovery and engineering, AI-Driven Industrial Biocatalysis for scale-up implementation, and AI-Driven Green Biocatalysis for sustainability-focused solutions. The first module reduces the design-build-test-learn cycle from 12-24 months to 8-12 months for moderately complex targets. The second addresses commercial production challenges such as substrate concentration optimization, cofactor regeneration, and product inhibition management, delivering complete technology transfer packages. The third module focuses on environmental benefits, as enzymatic reactions occur in aqueous media at room temperature, minimizing organic solvents, reducing emissions, and simplifying purification.
The platform's capabilities were demonstrated in a recent case study on transaminase engineering. Researchers developed a 6D protein engineering framework combining interaction energy, solvent effects, and 1.39 million structural fragments to predict beneficial mutations. Five AI-selected transaminase variants, each with nine mutations, showed high solubility and catalytic stability at 7-liter fermentation scale, converting prochiral ketones to sitagliptin with enantiomeric purity exceeding 99% and conversion rates up to 89% during scale-up production.
According to Creative Enzymes, the pharmaceutical industry is currently the biggest adopter of AI biocatalysis, particularly for asymmetric synthesis of chiral intermediates and replacing hazardous reagents. Agrochemicals and food sectors are also exploring the technology to fine-tune toxicology profiles and deliver cleaner labels through enzymatic modification, while fine chemicals and personal care industries are beginning to explore high-value conversions and milder, more sustainable processes.
